Identification of patients (pts) at high risk for early death with advanced or metastatic breast cancer (MBC), not receiving salvage treatment after 1st-line (1stL) therapy with trastuzumab (T) - Results of a prospective national non-interventional study (NIS) in Germany

被引：0
|
作者：
Jackisch, C.
Schoenegg, W.
Reichert, D.
Welslau, M.
Selbach, J.
Harich, H-D
Tesch, H.
Keitel, S.
Hinke, A.
机构：
[1] Sana Klinikum Offenbach GmbH, Offenbach, Germany
[2] Gynakol Praxis, Berlin, Germany
[3] Gemeinschaftspraxis Hamatol & Onkol, Westerstede, Germany
[4] Klinikum Aschaffenburg, Hamatoonkol Schwerpunktpraxis, Aschaffenburg, Germany
[5] Med Zentrum Duisburg Nord, Schwerpunktpraxis & Tagesklin, Duisburg, Germany
[6] Hamatol Onkol Schwerpunktpraxis, Hof, Germany
[7] Bethanien Krankenhaus, Hamatol Onkol Gemeinschaftspraxis, Frankfurt, Germany
[8] Roche Pharma AG, Grenzach Wyhlen, Germany
[9] WISP Res Inst, Langenfeld, Germany
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-P4-13-28
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-13-28
引用
下载
收藏
页数：2
相关论文
共 8 条
  • [1] 1st-line panitumumab plus FOLFIRI or FOLFOX for patients with RAS wildtype metastatic colorectal cancer in Germany: Interim results of the non-interventional study VALIDATE
    Uhlig, J.
    Potenberg, J.
    Semsek, D.
    Stuebs, P.
    Fichter, C. D.
    Koehler, A.
    Mueller, L.
    Reiser, M.
    Siebenbach, H. U.
    Goehler, T.
    Jacobasch, L.
    Kaechele, V.
    Timm, B.
    Potthoff, K.
    Marschner, N. W.
    ANNALS OF ONCOLOGY, 2020, 31 : S436 - S436
  • [2] Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958)
    Thill, Marc
    Wimberger, Pauline
    Grafe, Andrea
    Klare, Peter
    Luedtke-Heckenkamp, Kerstin
    Reichert, Dietmar
    Zaiss, Matthias
    Ziegler-Loehr, Katja
    Eckl, Tanja
    Schneeweiss, Andreas
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 196 (02) : 311 - 321
  • [3] Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958)
    Marc Thill
    Pauline Wimberger
    Andrea Grafe
    Peter Klare
    Kerstin Luedtke-Heckenkamp
    Dietmar Reichert
    Matthias Zaiss
    Katja Ziegler-Löhr
    Tanja Eckl
    Andreas Schneeweiss
    Breast Cancer Research and Treatment, 2022, 196 : 311 - 321
  • [4] Dual HER2-blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T. Results from a German non-interventional study (NIS) HELENA (NCT01777958)
    Thill, Marc
    Auth, Lead
    Grafe, Andrea
    Klare, Peter
    Luedtke-Heckenkamp, Kerstin
    Reichert, Dietmar
    Wimberger, Pauline
    Zaiss, Matthias
    Ziegler-Loehr, Katja
    Eckl, Tanja
    Schneeweiss, Andreas
    CANCER RESEARCH, 2022, 82 (04)
  • [5] Nora: Real World Evidence in Renal Cell Carcinoma; A National, Prospective, Non-Interventional Study in Patients with Advanced/Metastatic Renal Cell Carcinoma Starting 1st Line Nivolumab and Ipilimumab Combination Therapy or Nivolumab Monotherapy After Prior Therapy
    Mueeller-Huesmann, Harald
    Bedke, Jens
    Gruenwald, Viktor
    Belz, Hanjo
    Boegetnann, Martin
    Herber, Martin
    von der Heyde, Eyck
    Ivanyi, Philipp
    Kretzschmar, Albrecht
    Schostak, Martin
    Schultze-Seemann, Wolfgang
    Grimm, Marc-Oliver
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 75 - 75
  • [6] Primary analysis of study MO19391, an open-label safety study of bevacizumab (B) plus taxane-based therapy as 1st-line treatment of patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC)
    Smith, I. E.
    Biganzoli, L.
    Cortes-Funes, H.
    Stroyakovskiy, D.
    Franke, F. A.
    Chlistalla, A.
    Pierga, J-Y
    Thomssen, C.
    Pritchard, K.
    CANCER RESEARCH, 2009, 69 (02) : 286S - 286S
  • [7] CHARACTERISTICS OF PATIENTS WITH HER2-POSITIVE METASTATIC (MBC) OR LOCALLY ADVANCED BREAST CANCER (ABC), TREATED WITH TRASTUZUMAB (T) AS 1ST LINE-THERAPY AND PROGRESSION-FREE FOR AT LEAST 3 YEARS: INTERIM ANALYSIS OF THE LORHA STUDY
    Tredan, O.
    You, B.
    Beuzeboc, P.
    Coeffic, D.
    Lortholary, A.
    Fellous, M.
    Rouge, T. De La Motte
    Andre, F.
    Arnould, L.
    Ferrero, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 125 - 125
  • [8] The co-administration of pertuzumab (P) and trastuzumab (T) as a single infusion, followed by vinorelbine (V), in first-line (1L) treatment of HER2-positive locally advanced or metastatic breast cancer (MBC) patients (pts): VELVET study interim analysis.
    Andersson, Michael
    Lopez-Vega, Jose Manuel
    Petit, Thierry
    Zamagni, Claudio
    Donica, Margarita
    Kamber, Julia
    Perez, Edith A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
1